Marina Ritchie

TL;DR: The results show that COVID-19-associated chemosensory impairment is not limited to smell, but also affects taste and chemesthesis, and suggest that SARS-CoV-2 infection may disrupt sensory-neural mechanisms.

TL;DR: In this article, the authors examined racial and ethnic differences in recruitment methods and trial eligibility in a multisite preclinical AD trial, and found that participants from underrepresented groups were more frequently excluded for failure to meet cognitive inclusion criteria (eg, screen failures by specific inclusion criteria: 147 [45.5%] Black participants vs 1338 [26.2%] White participants).

TL;DR: In this article , the authors investigate whether reactions to AD biomarker disclosure differ among racial and ethnic groups in preclinical Alzheimer's disease (AD) trials, and they show that disclosure can be performed safely.

TL;DR: Willingness to participate in preclinical AD trials may have been negatively affected by the FDA's decision to approve aducanumab among those aware of the decision.

TL;DR: In this paper , the authors examined the trends in recruitment over a 20-year period of NIH-funded AD clinical trials conducted by the Alzheimer's Disease Cooperative Study (ADCS), a temporally consistent network of sites devoted to interventional research.